-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
We -X- _ O
have -X- _ O
previously -X- _ O
shown -X- _ O
that -X- _ O
HCC -X- _ O
patients -X- _ O
and -X- _ O
healthy -X- _ O
subjects -X- _ O
are -X- _ O
equally -X- _ O
responsive -X- _ O
to -X- _ O
a -X- _ O
RNAdjuvant -X- _ O
( -X- _ O
® -X- _ O
) -X- _ O
, -X- _ O
a -X- _ O
novel -X- _ O
TLR-7 -X- _ O
/ -X- _ O
8 -X- _ O
/ -X- _ O
RIG-I -X- _ O
agonist -X- _ O
based -X- _ O
on -X- _ O
noncoding -X- _ O
RNA -X- _ O
developed -X- _ O
by -X- _ O
CureVac -X- _ O
, -X- _ O
by -X- _ O
an -X- _ O
ex -X- _ O
vivo -X- _ O
evaluation. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
immunological -X- _ O
effect -X- _ O
of -X- _ O
adjuvants -X- _ O
on -X- _ O
immune -X- _ B-Patient
cells -X- _ I-Patient
from -X- _ I-Patient
cancer -X- _ I-Patient
patients -X- _ I-Patient
undergoing -X- _ I-Patient
chemotherapy -X- _ I-Patient
remains -X- _ O
to -X- _ O
be -X- _ O
demonstrated. -X- _ O
Different -X- _ B-Intervention
adjuvants -X- _ I-Intervention
currently -X- _ O
used -X- _ O
in -X- _ O
cancer -X- _ O
vaccine -X- _ O
clinical -X- _ O
trials -X- _ O
were -X- _ O
evaluated -X- _ O
in -X- _ O
the -X- _ O
present -X- _ O
study -X- _ O
on -X- _ O
immune -X- _ B-Patient
cells -X- _ I-Patient
from -X- _ I-Patient
cancer -X- _ I-Patient
patients -X- _ I-Patient
before -X- _ I-Patient
and -X- _ I-Patient
after -X- _ I-Patient
chemotherapy -X- _ I-Patient
in -X- _ O
an -X- _ O
ex -X- _ O
vivo -X- _ O
setting. -X- _ O
METHODS -X- _ O
: -X- _ O
PBMCs -X- _ O
were -X- _ O
obtained -X- _ O
from -X- _ O
4 -X- _ B-Comparison
healthy -X- _ I-Comparison
volunteers -X- _ I-Comparison
and -X- _ O
23 -X- _ B-Patient
patients -X- _ I-Patient
affected -X- _ I-Patient
by -X- _ I-Patient
either -X- _ I-Patient
colon -X- _ I-Patient
( -X- _ I-Patient
OMA -X- _ I-Patient
) -X- _ I-Patient
or -X- _ I-Patient
lung -X- _ I-Patient
cancer -X- _ I-Patient
( -X- _ I-Patient
OT -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
The -X- _ O
effect -X- _ O
of -X- _ O
CpG -X- _ B-Intervention
, -X- _ I-Intervention
Poly -X- _ I-Intervention
I -X- _ I-Intervention
: -X- _ I-Intervention
C -X- _ I-Intervention
, -X- _ I-Intervention
Imiquimod -X- _ I-Intervention
and -X- _ I-Intervention
RNA-based -X- _ I-Intervention
adjuvant -X- _ I-Intervention
( -X- _ I-Intervention
RNAdjuvant -X- _ I-Intervention
( -X- _ I-Intervention
® -X- _ I-Intervention
) -X- _ I-Intervention
) -X- _ I-Intervention
was -X- _ O
assessed -X- _ O
using -X- _ O
a -X- _ O
multiparametric -X- _ O
approach -X- _ O
to -X- _ O
analyze -X- _ O
network -X- _ O
dynamics -X- _ O
of -X- _ O
early -X- _ O
immune -X- _ O
responses. -X- _ O
Evaluation -X- _ O
of -X- _ O
CD80 -X- _ O
, -X- _ O
CD86 -X- _ O
and -X- _ O
HLA-DR -X- _ O
expression -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
the -X- _ O
downstream -X- _ O
effect -X- _ O
on -X- _ O
CD4 -X- _ O
( -X- _ O
+ -X- _ O
) -X- _ O
T -X- _ O
cell -X- _ O
phenotyping -X- _ O
was -X- _ O
performed -X- _ O
by -X- _ O
flow -X- _ O
cytometry -X- _ O
; -X- _ O
cytokine -X- _ O
and -X- _ O
chemokine -X- _ O
production -X- _ O
was -X- _ O
evaluated -X- _ O
by -X- _ O
Bio-Plex -X- _ O
ProTM. -X- _ O
RESULTS -X- _ O
: -X- _ O
Treatment -X- _ B-Outcome
with -X- _ I-Outcome
RNAdjuvant -X- _ I-Outcome
( -X- _ I-Outcome
® -X- _ I-Outcome
) -X- _ I-Outcome
induced -X- _ I-Outcome
the -X- _ I-Outcome
strongest -X- _ I-Outcome
response -X- _ I-Outcome
in -X- _ I-Outcome
cancer -X- _ I-Outcome
patients -X- _ I-Outcome
in -X- _ I-Outcome
terms -X- _ I-Outcome
of -X- _ I-Outcome
activation -X- _ I-Outcome
of -X- _ I-Outcome
innate -X- _ I-Outcome
and -X- _ I-Outcome
adoptive -X- _ I-Outcome
immunity. -X- _ I-Outcome
Indeed -X- _ I-Outcome
, -X- _ I-Outcome
CD80 -X- _ I-Outcome
, -X- _ I-Outcome
CD86 -X- _ I-Outcome
and -X- _ I-Outcome
HLA-DR -X- _ I-Outcome
expression -X- _ I-Outcome
was -X- _ I-Outcome
found -X- _ I-Outcome
upregulated -X- _ I-Outcome
in -X- _ I-Outcome
circulating -X- _ I-Outcome
dendritic -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
promoted -X- _ I-Outcome
a -X- _ I-Outcome
CD4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
differentiation -X- _ I-Outcome
towards -X- _ I-Outcome
an -X- _ I-Outcome
effector -X- _ I-Outcome
phenotype. -X- _ I-Outcome
RNAdjuvant -X- _ I-Outcome
( -X- _ I-Outcome
® -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
the -X- _ I-Outcome
only -X- _ I-Outcome
one -X- _ I-Outcome
to -X- _ I-Outcome
induce -X- _ I-Outcome
most -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
cytokines -X- _ I-Outcome
/ -X- _ I-Outcome
chemokines -X- _ I-Outcome
tested -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
pronounced -X- _ I-Outcome
Th1 -X- _ I-Outcome
cytokine -X- _ I-Outcome
pattern. -X- _ I-Outcome
According -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
different -X- _ I-Outcome
parameters -X- _ I-Outcome
evaluated -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
study -X- _ I-Outcome
, -X- _ I-Outcome
no -X- _ I-Outcome
clear -X- _ I-Outcome
cut -X- _ I-Outcome
difference -X- _ I-Outcome
in -X- _ I-Outcome
immune -X- _ I-Outcome
response -X- _ I-Outcome
to -X- _ I-Outcome
adjuvants -X- _ I-Outcome
was -X- _ I-Outcome
observed -X- _ I-Outcome
between -X- _ I-Outcome
healthy -X- _ I-Outcome
subjects -X- _ I-Outcome
and -X- _ I-Outcome
cancer -X- _ I-Outcome
patients. -X- _ I-Outcome
Moreover -X- _ I-Outcome
, -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
latter -X- _ I-Outcome
group -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
chemotherapy -X- _ I-Outcome
treatment -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
consistently -X- _ I-Outcome
correlate -X- _ I-Outcome
to -X- _ I-Outcome
a -X- _ I-Outcome
significant -X- _ I-Outcome
altered -X- _ I-Outcome
response -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
different -X- _ I-Outcome
parameters. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
The -X- _ O
present -X- _ O
study -X- _ O
is -X- _ O
the -X- _ O
first -X- _ O
analysis -X- _ O
of -X- _ O
immunological -X- _ O
effects -X- _ O
induced -X- _ O
by -X- _ O
adjuvants -X- _ O
in -X- _ O
cancer -X- _ O
patients -X- _ O
who -X- _ O
undergo -X- _ O
chemotherapy -X- _ O
, -X- _ O
who -X- _ O
are -X- _ O
enrolled -X- _ O
in -X- _ O
the -X- _ O
currently -X- _ O
ongoing -X- _ O
cancer -X- _ O
vaccine -X- _ O
clinical -X- _ O
trials. -X- _ O
The -X- _ O
results -X- _ O
show -X- _ O
that -X- _ O
the -X- _ O
RNAdjuvant -X- _ B-Outcome
( -X- _ I-Outcome
® -X- _ I-Outcome
) -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
potent -X- _ I-Outcome
and -X- _ I-Outcome
Th1 -X- _ I-Outcome
driving -X- _ I-Outcome
adjuvant -X- _ I-Outcome
, -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
those -X- _ I-Outcome
tested -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
present -X- _ I-Outcome
study. -X- _ I-Outcome
Most -X- _ O
importantly -X- _ O
, -X- _ O
it -X- _ O
is -X- _ O
demonstrated -X- _ O
that -X- _ O
chemotherapy -X- _ B-Outcome
does -X- _ I-Outcome
not -X- _ I-Outcome
significantly -X- _ I-Outcome
impair -X- _ I-Outcome
the -X- _ I-Outcome
immune -X- _ I-Outcome
system -X- _ I-Outcome
, -X- _ O
implying -X- _ O
that -X- _ O
cancer -X- _ O
patients -X- _ O
are -X- _ O
likely -X- _ O
to -X- _ O
respond -X- _ O
to -X- _ O
a -X- _ O
cancer -X- _ O
vaccine -X- _ O
even -X- _ O
after -X- _ O
a -X- _ O
chemotherapy -X- _ O
treatment -X- _ O
. -X- _ O

